Name:	vorinostat
DrugBank ID:	DB02546
Structure:
Description:	Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs. [Wikipedia]
Association:   figure	Small molecule miRNA P-value Correlation vorinostat hsa-miR-181c 0 negative vorinostat hsa-miR-368 0 positive vorinostat hsa-miR-188 0.00002 negative vorinostat hsa-miR-30e-5p 0.00006 positive vorinostat hsa-miR-494 0.00108 negative vorinostat hsa-miR-101 0.0012 negative vorinostat hsa-miR-130a 0.01547 negative vorinostat hsa-miR-148b 0.01778 positive vorinostat hsa-miR-20b 0.02544 negative TotalPage:1, CurrentPage:1  First  Prev Next  Last